KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trial.

Martin S Maron, Juan Ramon Gimeno, Josef Veselka, Roberto Barriales-Villa, Brian L Claggett, Caroline J Coats, Sheila M Hegde, James L Januzzi, Ian J Kulac, Ahmad Masri, Michael E Nassif, John A Spertus, Daniel L Jacoby, Stephen B Heitner, Stuart Kupfer, Fady I Malik, Amy Wohltman, Iacopo Olivotto

Eur Heart J 46(40) 4076-4086

PMID41120118
PMCIDPMC12539928
DOI10.1093/eurheartj/ehaf364
发表日期2025-10-21
入排依据:未发现恶性肿瘤人群证据。
已检查 3 张 PubMed Figure,均未识别为 KM 图:Structured Graphical Abstract:AI 判定为 other;Figure 1:AI 判定为 other;Figure 2:AI 判定为 flow diagram。
摘要

摘要

BACKGROUND AND AIMS: Patients with obstructive hypertrophic cardiomyopathy (oHCM) treated with aficamten in SEQUOIA-HCM (NCT05186818) demonstrated marked improvement in symptoms and functional capacity. This analysis explores whether oHCM and mild symptoms patients experience similar clinical benefits with aficamten as patients with more advanced limitations. METHODS: Patients in SEQUOIA-HCM (N = 282) were grouped at baseline according to symptom severity. Mild symptoms (n = 118) were defined as New York Heart Association (NYHA) class II and Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) ≥ 80, and moderate to severe symptoms (n = 150) as NYHA class II/III/IV and KCCQ-CSS <80. Primary endpoint was change in peak oxygen uptake (pVO2) from baseline to Week 24; secondary endpoints included change in NYHA class, KCCQ-CSS, outflow tract gradients, and N-terminal pro-B-type natriuretic peptide (NT-proBNP). RESULTS: In aficamten-treated patients, change at Week 24 was not different between moderate to severe (1.8 mL/kg/min; n = 71) and mild (1.6 mL/kg/min; n = 62) symptom groups (P = .8). Likewise, the change in secondary endpoints (NYHA class, resting or Valsalva gradients, and NT-proBNP) did not differ significantly between the two symptom groups. Both groups experienced statistically significant improvements in KCCQ-CSS, but the extent of improvement was greater in the advanced symptom group (P = .02 for interaction). Treatment-emergent serious adverse events were infrequent in both groups. CONCLUSIONS: Patients with oHCM and mild symptoms treated with aficamten achieved significant improvement across a range of clinically relevant outcomes and generally similar to patients with more advanced symptoms. Less severely symptomatic patients could be considered for aficamten treatment.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Structured Graphical AbstractStructured Graphical Abstract Aficamten in obstructive HCM with mild symptoms. Patients with oHCM and mild symptoms at baseline treated with aficamten over 24 weeks demonstrate significant improvement in clinical outcome measures and, compared with patients with oHCM and moderate to severe symptoms treated with aficamten, the magnitude of changes in clinical outcomes is similar. * Except P value for comparison of KCCQ-CSS between groups, which was statistically significant. KCCQ-CSS, Kansas City Heart Failure Questionnaire-Clinical Summary Score; NYHA, New York Heart Association; oHCM, obstructive hypertrophic cardiomyopathy.
非 KM Figure
Figure 1Figure 1 Key Primary and secondary outcomes in patients with symptomatic oHCM treated with aficamten. Shown are mean changes from BL to Week 24 in ( A ) pVO 2 , ( B ) KCCQ-CSS, ( C ) Valsalva LVOT-G, and ( D ) NT-proBNP in patients with oHCM and mild vs. moderate to severe symptoms treated with aficamten vs. placebo. P values refer to the change in outcome from baseline to Week 24 in patients with oHCM and mild or moderate to severe symptoms treated with aficamten as compared with placebo. BL, baseline; KCCQ-CSS, Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score; LVOT-G, left ventricular outflow tract gradient; NT-proBNP, N-terminal pro–B-type natriuretic peptide; oHCM, obstructive hypertrophic cardiomyopathy; pVO 2 , peak oxygen uptake
非 KM Figure
Figure 2Figure 2 Changes in symptom burden and health status from baseline to Week 24. Transition in NYHA functional class and KCCQ-CSS from BL to completion of the 24-week treatment period in aficamten-treated patients with ( A ) mild symptoms and ( B ) moderate to severe symptoms. BL, baseline; KCCQ-CSS, Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score; NYHA, New York Heart Association; oHCM, obstructive hypertrophic cardiomyopathy
非 KM Figure